Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Annals of the Rheumatic Diseases

Pos0733 Validation of the Sle-Das Responder Index as an Accurate and Feasible Endpoint for Sle Clinical Trials: A Post-Hoc Study in the Phase 2 and 3 Anifrolumab Clinical Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

DJDiogo JesúsUniversity of Beira InteriorCHC. HenriquesPolytechnic Institute of ViseuAMAna MatosAdministração Regional de Saúde de Lisboa e Vale do Tejo

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jesús et al. (2024) studied this question.

synapsesocial.com/papers/68e671b1b6db6435875fbc06https://doi.org/10.1136/annrheumdis-2024-eular.4639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials2024
  2. 2P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials2024
  3. 3O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials2024
  4. 4P60 Performance of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients2024
  5. 5SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2–3 trials2026